dual gip/glp-1 receptor agonist Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research LY3437943, a novel triple glucagon,

5 Conclusion In conclusion, compared to monotherapy, GLP-1RA and SGLT-2i combination therapy can more effectively improve blood glucose levels, reduce weight, and control systolic blood pressure in patients with type 2 diabetes

Liraglutide (a daily injection) resulted in a more modest average weight reduction of around 45%, based on 24 trials (9 937 participants), but still increased the proportion of people achieving meaningful weight loss compared with placebo

Real-world evidence shows GLP-1 agonists lower the need for percutaneous coronary interventions and other revascularization procedures especially in patients who have already had an MI [61]

We performed time-based analysis on changes in body weight with GLP-1 RA as summarised in Fig

Regional Snapshot 20.3

Predictive biomarkers: Further evidence should emerge in identifying predictive biomarkers that could help identify which patients are most likely to benefit from GLP-1 RAs and SGLT2is, and their combination, in the management of PCOS